Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $474
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Vertex Pharmaceuticals and raises the price target from $462 to $474.
October 01, 2024 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on Vertex Pharmaceuticals while increasing the price target from $462 to $474, indicating a positive outlook.
The increase in the price target from $462 to $474 by Morgan Stanley suggests a positive outlook for Vertex Pharmaceuticals, which could lead to a short-term increase in stock price. The maintained Equal-Weight rating indicates a balanced view, but the raised target price is a positive signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100